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The steroid hormones estrogen and progesterone 
are involved in the growth and functions of. the normal 
mammary gland, and many mammary tumors retain their 
dependence on those hormones. Steroids exert their 
influence through binding to cytoplasmic receptor 
proteins which act in the nucleus after binding steroid 
molecules. The presence or absence of steroid re-
ceptors may thus be an indicator of the retention or 
loss of endocrine regulation. In this study, mammary 
carcinomas were induced in female Sprague-Dawley rats by 
a single feeding of the chemical carcinogen 7,12-
dimethylbenz(a) anthracene. Animals with tumors were 
subjected to bilateral oophorectomy and tumors were 
grouped according to response. Tumors which regressed 
completely were termed hormone-dependent, and those 
which continued to grow were termed hormone-independent. 
Tumors were analyzed for estrogen and progesterone 
binding sites, both cytoplasmic and nuclear, and the 
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hormone-dependent and hormone-independent groups were 
compared based upon the presence or absence of steroid 
receptors, distribution of receptors in cytosol and 
nuclear compartments, binding site concentrations, and 
dissociation constants of ligand-receptor complexes. 
There was a positive correlation between estrogen 
receptor positivity and tumor regression in response to 
oophorectomy. While the presence or absence of pro-
gesterone receptor alone was not predictive of response 
to oophorectomy, the presence of progesterone receptor 
when estrogen receptor was also present improved the 
correlation. Mean binding site concentrations for both 
steroids were higher in the hormone-dependent group. 
Analysis of dissociation constants indicated high 
affinity binding sites for both steroids with no 
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Much of our understanding of steroid hormone mecha-
nism of action has derived from investigations of steroid 
interaction with normal target tissues such as uterus, 
vagina, anterior pituitary, and mammary gland (1). 
Jensen and Jacobson (2), as well as Folca et al (3), 
initially reported the in vivo uptake and retention of 
labeled estrogens by target tissues against concentra-
tion gradients. Jensen and co-workers first succeeded in 
synthesizing carrier-free tritiated estradiol 17-beta, 
and shortly thereafter demonstrated that•target tissue 
localization of estradiol results from the presence of 
unique binding components characterized by high affinity 
and ligand specificity (.4, 5). These components have 
been designated "estrogen receptors." An essential char-
acteristic of an estrogen target cell is the ability to 
specifically bind estradiol 17-beta with high affinity (1). 
Steroid hormone receptors are soluble proteins which 
probably play a key role in the mechanism of action of the 
steroid hormones (6). The presence of receptor appears to < 
be prerequisite for cellular response to changes in 




By incubation of cytosol with tritiated (
3
H) 
estradiol 17-beta and subsequent sedimentation through a 
' 
linear gradient of sucrose, specific estrogen binding 
components can be identified and characterized, by deter-
mining the distribution of radioactivity in gradient 
regions. Specificity of binding is assured by parallel 
incubations with excess unlabeled estradiol or a com-
petitive inhibitor. The difference in 3H estradiol bound 
-in the presence and absence of inhibitor provides a 
'' measure of specific estrogen binding capacity (1). The 
hormone receptor complex of normal breast cytosol sedi-
ments at 8-9 S (.Svedbergs) on sucrose gradients of low 
salt concentration and a 4-5 Son sucrose gradients of 
high salt concentra_tion (8). Both the 8-9 S and the 4-5 
S forms are apparently protein in nature as they are 
sensitive to pronase digestion, but insensitive to 
nuclease digestion (1). At physiologic salt concentration 
(.15 M) the cytosol hormone receptor complex sediments at 
6 S (9). 
The sedimentation profiles of estrogen and progeste-
rone receptors in mammary carcinoma cytosol preparations 
fall into four general categories: migration at 8-9 S, 
migration at 4-5 S, migration at both 8-9 Sand 4-5 S, 
and undetectable (10, 11). The presence of the 4 S form 
3 
in low salt buffers appears to be restricted to 
neoplastic tissue, as it has been demonstrated only in 
rodent and human mammary carcinoma (12). 
Steroid Hormone Mechanism of Action 
The series of steps in the interaction of steroid 
hormones with their target cells, as currently understood 
(see Fig. 1), has evolved from the two step mechanisms pro-
posed independently by Gorski et al (13) and Jensen et al 
(14) in 1968. Steroid hormones are transported in the 
plasma by a number of proteins including albumin, sex 
steroid binding globulin (SSBG), and corticosteroid 
binding globulin (CBG) (15). Unbound steroid enters the 
cell by passive diffusion and combines with cytoplasmic 
receptor in an association characterized by high affinity 
and ligand specificity (16). In the case of estradiol, 
it has been proposed that binding occurs onto a 4 S 
binding subunit of the 8 S receptor followed by a temper-
ature dependent 4 S to 5 S transformation and subsequent 
translocation to the nucleus (6). The nuclear hormone 
receptor complex then associates with chromatin (6); 
resulting in stimulation of messenger RNA synthesis and 
the subsequent formation of cellular proteins (17, 18). 
The nature of the departure and fate of the nuclear 
hormone receptor complex is unknown (1). 
Cellular replication and differentiation appear to 
result from this cascade of events, when intact (12). 
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Evidence suggests that the basis for the 4 S to 5 S 
transformation is dimerization of the 4 S subunit with 
a second·subunit. Wittliff has proposed that estrogen 
receptor of normal breast and responsive tumors consists 
of subunits which combine in the presence of estradiol to 
form a "6 S" dimer which then translocates to the nucleus. 
Chromatin binding i~ vitro is directly proportional 
to available estrogen receptor complex, and shows non-
competitive, "unsaturable" behavior. In one study, 
target and non-target muclei in cell free systems bound 
3000-4000 molecules of 3H estradiol receptor complex per 
nucleus (19). The rate of hormone receptor complex 
binding to chromatin in vitro is temperature dependent 
and incubation of both estrogen receptor complex and 
chromatin at 21° C is necessary for significant 
association to occur (20). 
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Figure 1.. Proposed Steps in Steroid Hormone/Target Cell 
Interaction. The steroid is designated as S, 
the cytoplasmic receptor as Re, and the 
nuclear form as Rn. Taken from Wittliff (16). 
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Hormone Interactions 
Normal breast contains specific binding sites for 
estrogens, progestins, corticoids, androgens, prolactin, 
growth hormone, and insulin (21). Estrogen and prolactin 
are the two primary hormones in breast growth regulation 
(22). Estrogens and progestins stimulate epithelial cell 
differentiation for milk protein synthesis and secretion 
(23). Estrogen also stimulates the release of pituitary 
prolactin which is regulatory for alveolar morphogenesis 
and mammary gland function (24). A model of complete 
endocrine regulation of breast tissue must include the 
interaction of these various hormones (22). 
Endocrine Therapy 
Surgical interference with endogenous production of 
estrogens as palliative therapy for mammary cancer was 
first suggested by Sir George Beatson in 1896 in a report 
describing the remission of advanced cancer in two women 
following bilateral oophorectomy (25). The biochemical 
mechanism of this phenomenon remains incompletely under-
stood (21). Either removal of endocrine producing 
organs or administration of pharmacologic doses of 
hormones results in objective remissions in 25-40% of 
patients with advanced breast disease (26). 
The concept underlying endocrine therapy is that 
certain tumor cells retain the ability to respond to the 
7 
same hormonal perturbations as their normal progenitors 
( 1) . That is, certain cancer cells are dependent on o_ne 
or more hormones and succumb when deprived of supporting 
hormones or when pharmacologic levels of hormone are 
administered (26). 
Human and experimental breast tumors which regress 
following endocrine therapy frequently contain a cyto-
plasmic protein that specifically binds estradiol with 
high affinity (9). It is assumed that the presence of 
estrogen receptor (ER) in breast tumor is due to the 
expression of a phenotypic characteristic of the normal, 
hormonally responsive cell line of origin (1). Cells 
which have undergone malignant transformation may retain 
all or only part of the normal receptor population, and, 
in theory at least, hormonal control should be absent in 
the absence of specific receptor (26). 
The observation, as previously noted, that labeled 
estrogens are localized in highest concentrations in 
estrogen target organs, led to the suggestion by Jensen 
et al that the ability of breast tumor to bind estrogen 
might be predictive of responsive to endocrine therapy 
(5). This idea was supported by their later findings in 
which the presence of estrogen receptor in tumor biopsies 
correlated with favorable response to adrenalectomy (10), 
and by the observation of Folca et al that when 
8 
tritiated hexestrol was administered to breast cancer 
patients prior to adrenalectomy, metastases which sub-
sequently regressed concentrated a larger fraction of the 
labeled estrogen than those which failed to respond (3). 
A corre,lation between the presence of estrogen receptor 
in breast tumor biopsy material and favorable response to 
endocrine therapy was presently confirmed in the labora-
tories of Wittliff and McGuire (27, 28). 
Endocrine additive and ablative therapies are 
interventions not without potentially serious compli-
cations. Methods of accurate selection could spare 
critically ill patients in whom endocrine therapy is 
unlikely to succeed from unnecessary treatment (1). An 
expansion of steroid binding data has followed to the 
present, and, while it remains true that estrogen 
receptor negative tumors rarely respond to endocrine 
therapy, the response of ER positive tumors varies over 
a wide range (see Table 1) (29). It is now generally 
accepted that selection of patients by estrogen receptor 
analysis improves the response rate to endocrine therapy 
by at least two-fold over non-selected cases (16). It 
has also been suggested that ER negative tumors tend to 
have higher mitotic rates as estimated by thymidine 
labeling, and that these more rapidly growing tumors 
might be expected to respond more favorably to cell cycle 
phase specific cytotoxic chemotherapy (30). 
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Table 1. Relationship Between Estrogen Receptor Status 
and Objective Response to Endocrine Therapy. 
Taken from Wittliff et al (7). 
INVESTIGATOR 
Blarney et al 
Dao and Nemoto 
DeSombre and Jensen 
Maass et al 
Manni et al 
McCarty~! al 
Nomura et al 
Osborne et al 
Paridaens et al 
Rubens and Hayward 
Sing kowinta et al 
Skinner et al 
Wittliff 
















522/977 (53%) 36/567(6%) 
Specific receptor for progesterone has also been 
identified .in breast tumor cytosols (11). Improved 
response rates to endocrine therapy in ER positive tumors 
has been reported if specific progesterone receptor (PR) 
is also present (See Table 2) (31), It has been 
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demonstrated that following oophorectomy, cytosol 
progesterone receptor levels diminish while cytosol ER 
levels remain high (32). As the synthesis of progeste-
rone receptor may be estrogen dependent the suggestion 
has arisen that PR positivity might simply be a reflection 
of ER concentration (29). This concept is complicated by 
the puzzling observation that tumors which are ER 
negative but PR positive (an enigma in theory) often 
respond to endocrine manipulation (See Table 2) (33). 
In any event, it is currently accepted that steroid re-
ceptor analysis in mammary carcinoma allows for prediction 
of response to endocrine therapy, and that the rate of 
response is highest when both ER and PR are present (34). 
'Failure to Respond 
Many tumors which contain specific estrogen binding 
proteins do not respond to endocrine maneuvers. The 
capacity to bind estrogen, therefore, does not obligate 
a biological response to the hormone (26). Events 
beyond the level of binding to receptor may be defective, 
such as receptor transformation (4 S - 5 S), translocation 
to the nucleus, and binding into chromatin (1). 
Thus, given the multiple subunit model of lvittliff, 
certain unresponsive breast cancers could contain 
specific estrogen binding protein, but not the full 
complement of receptor subunits necessary for 
. ,
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transformation and translocation (16). This may also 
explain, at least in part, the improved response rates of 
tumors when both ER and PR are present. The response of 
progesterone receptor, assuming the dependence of PR 
synthesis on estrogen stimulation, would rule out a defect 
in estrogen interaction beyond the level of binding to 
receptor (35). 
Table 2. Relationship Between Estrogen and Progesterone 
Receptor Status and Objective Response to 
Endocrine Therapy. Taken from Wittliff et al 
( 33) . 
STEROID. RECEPTOR STATUS 
INVESTIGATOR 
Brooks et ·al 
Dao and Nemoto 
4/6 
10/13 
Degenshein et al. 26/33 
King 10/11 
McCarty et al 33/40 
Nomura et al 7/10 
Osborne et al 
Skinner et al 




































Another factor which may enter into the failure of 
receptor positive tumors to respond to endocrine manip-
ulation is the heterogeneity of tumors with regard to 
cellular composition. While the receptor concentration 
by assay represents an integrated value for the entire 
biopsy, the actual concentration of receptor may vary 
widely from cell to cell. Tumor biopsies which are 
receptor (R) positive are likely to include a variable 
number of receptor negative cells. It may be that 
hormone dependent cells atrophy as a result of milieu 
alterations, while hormone independent cells continue to 
proliferate. This theory is complicated by the obser-
vation that in tumors which regress following 
oophorectomy and then resume growth (obstensibly due to 
proliferation of the hormone independent sub-population) 
a second remission can be induced by further ablative 
therapy such as adrenalectomy or hypophysectomy. A 
possible explanation for this phenomenon is that regrowth 
included both receptor positive and receptor negative 
cells, with peripheral conversion of androstenedione to 
estrone allowing R positive cells to participate. 
Adrenalectomy or hypophysectomy would eliminate the 
adrenal source of estrogen precursors, allowing for the 
second regression of R positive cells. In reality, tumor 
cell subpopulations may represent a continuum of varying 
" 
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receptor populations in varying concentrations, and dif-
ferent endocrine therapies may be affecting different 
levels of endocrine regulation (21). There is no 
apparent correlation between tumor histology and hormone 
binding capacity (1, 16, 21). 
The pituitary hormone prolactin has also been impli-
cated in experimental mammary tumorogenesis and prolactin 
receptor has been demonstrated in membrane fractions of 
mammary tumor cells. It is theorized that prolactin 
dependence requires the presence of cell surface 
receptors (36). It has been shown that prolactin can 
stimulate estrogen receptor in mammary tumors and addi-
tionally prolactin may be responsible for progesterone 
receptor synthesis- (21). - Physiologic .. amounts _of estrogen 
may enhance prolactin receptor levels wherea_s pharma-
cologic doses of estrogen may reduce receptor levels as 
an antagonist at the tissue level (24). It has been 
reported that elevation of serum prolactin results in an 
increase in the size and number of dimethybenz(a) anthra-
cene (DMBA) induced mammary carcinomas, and can 
reactivate tumor growth following oophorectomy, adrena-
lectomy and hypophysectomy (37). Further, reduction of 
serum prolactin results in inhibition of growth of 
spontaneous and DMBA induced rat mammary tumors (38). 
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Prolactin also participates in the development and 
progression of some human mammary cancer, but the rela-
tionship is poorly understood, and human tumors may be 
less sensitive to prolactin than experimental tumors 
(39). However, prolactin dependency may explain why 20% 
of estrogen receptor and progesterone receptor positive 
tumors fail to respond to endocrine therapy (40). 
The relationship between receptor level and biolog-
ical response is complicated and unless receptor concen-
tration is rate limiting, significant differences in 
receptoreceptor level may occur without significant 
differences in hormone response (24). Prediction of 
hormone dependency by steroid receptor status may be 
something of an oversimplification, but loss of receptor 
may at least be viewed as indicative of departure from 
normality (9). 
Titration Analysis 
Sucrose gradient centrifugation (as previously 
described) and titration assay are generally recognized 
as the most acceptable methods of receptor analysis 
(33). In titration analysis, tissue preparations are 
equilibrated with increasing quantities of radioactive 
hormone, where, under appropriate conditions of pH and 
temperature, the radiolabeled hormone combines with 
receptor, if present, and forms the hormone receptor 
complex (16). 
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Estimations of receptor affinity and binding site 
concentrations require separation of bound from free 
hormone. A number of techniques have been employed for 
this purpose including electrophoresis, chromatography, 
dextran coated charcoal (DCC) adsorption of free steroid, 
protamine sulfate protein precipitation, and protein 
adsorption to hydroxylapatite (41). 
Hydroxylapatite [3Ca3 (P04 ) 2 . Ca(OH) 2 J is a 
homogenous insoluble chemical which can be obtained in 
analytical grade quantities of uniform particle size, 
and which can readily be pelleted or resuspended. The 
hydroxylapatite technique involves adsorption of protein 
bound tritiated hormone onto hydroxylapatite particles, 
separation from the liquid phase by centrifugation, 
sequential washes with buffer to remove residual unbound 
hormone, extraction of tritiated hormone adsorbed to 
hydroxylapatite pellet into ethanol, and quantitation of 
bound activity by scintillation counting. Hormone 
receptor adsorption to hydroxylapatite appears to be un-
affected by increasing ionic strength up to 2.5 Mand is 
therefore of value in quantitating nuclear hormone recep-
tor complex as well, which is generally defined as 
extractable in buffer containing .3 - .6 M KCl (41). 
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Additionally, hydroxylapatite shows little affinity for 
free steroid, adsorption can be carried out at O - 2° C, 
and the hydroxylapatite method is more accurate than 
the DCC method at low protein concentrations (42). 
Most tissue preparations contain, in addition to 
specific high affinity receptors, other low affinity, high 
capacity, "non-specific" binding components such as plasma 
contaminants (43). Estimations of receptor parameters 
rely on separation of, or correction for, binding to 
non-specific components and the use of equations based on 
the law of mass action for the interaction of the steroid 
(S) and a single class of receptor (R) given by: 
S + R :::;;:= S • R (44). The widely used method of 
correction for non-specific binding involves equilibration 
of tissue preparations with increasing concentrations of 
radioactive steroid, and in parallel incubations specific 
binding is inhibited by addition of radioinert ligand or 
competitive inhibitor. Specific binding can be deter-
mined by the difference between total bound activity in 
the absence of competitor and the amount of non-specific 
binding which occurs in the presence of excess competitor 
( 4 5 l • 
In routine steroid receptor assay, many laboratories 
present their results in the form of a Scatchard plot 
(46), where the x-variable is B and they - variable is 
s 
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Bs / F (47). BT - BNS = BS, where BT is total bound 
activity in the absence of competitor, BNS is activity 
bound "non-specifically'' in the presence of excess com-
petitor, and BS is specifically bound activity (44, 47). 
For methods which estimate the bound moiety (such as the 
hydroxylapatite method) the unbound or free moiety (Fl is 
estimated by subtracting total bound from total ligand 
present, or: T - B = F 
T 
( 4 3) • 
After plotting points obtained from several concen-
trations, a straight line is fitted, least squares 
regression analysis being the usual formal method (47). 
For points on the graph described by (X1 , Y1 ) {X 2 , Y2 l··· 
(X , Y ), the equation of the line fitted to such points 
n n 
is: y = mx + b; where mis the slope of the line and b 
is the Y intercept. For least squares regression analysis 







°2 (Xl - X) 2 
(48). The intercept of the line 
with the ordinate, b, is given by: b = Y - m X. The 
intercept of the line with the abscissa, Bmax' can then 
be calculated by: Y = m x + b; setting Y = 0: 
B = max 
b 
m 
{ 4 8) • As long as Bis used with the same 
units for plotting both BS and BS/ F, a valid plot 
results whose B intercept (Bmax) is an estimate of 
18 
binding site concentration and whose slope is - 1/Kd, 
where Kd is the dissociation constant of the hormone re-
ceptor complex (45). 
In a system with two descrete levels of specific 
activity, binding parameters can be calculated in terms of 
count rates and converted to molar concentrations for 
final binding parameters (43). Binding capacity is 
-15 
usually expressed as femptomoles (10 M) of binding 
sites per milligram of cytosol protein (49). 
Sources of Error 
Titration analysis measures only unoccupied receptor. 
Theoretically only tissues with small receptor concen-
trations should be affected by receptor occupancy by 
endogenous hormone, but under some circumstances sub-
stantial dilution of radioactive steroid by dissociation 
of endogenous hormone from high capacity non-specific 
components during equilibration may distort estimates of 
receptor parameters. Also, some steroids are readily 
adsorbed to glass or plastic surfaces. Since either the 
bound or the unbound fraction is estimated by the differ-
ence between the total steroid added and the moiety 
quantitated, systematic errors can arise if steroid is 
lost by adsorption. Overestimates of bound steroid 
result in over estimates of binding site concentration 
and underestimates of Kd, whereas overestimates of 
19 
unbound· steroid result in overestimates of Kd, but do not 
affect binding site estimates (43). When excess radio-
inert ligand is used to correct for non-specific binding, 
a problem can arise at high ligand concentrations, where 
competition can occur for binding components of relatively 
low affinity (45). 
Carcinogen_esis 
It is established that the mammary gland is sensitive 
to the actions of carcinogens and is a major site for the 
concentration of dimethylbenz(a)-anthracene (DMBA) and 
trimethylbenz(a) anthracene (TMBA) (50). Both 7,12 DMBA 
and 7,8,12 TMBA are highly carcinogenic, characterized by 
multiplicity of tumors and rapidity of carcinogenesis. 
Carcinogenicity of aromatic hydrocarbons is associated 
with their ability to form charge transfer complexes with 
local acceptors and donate an electron. There is· also a 
direct increase in carcinogenicity as hydrocarbons become 
sterically similar to steroids. There is a remarkable 
steric similarity between carcinogenic polynuclear 
aromatic hydrocarbons, growth promoting steroids, and 
nucleic acid base pairs. Based on experimental data, 
Huggins made the following proposition: "Every 50 day 
old, intact, female rat of the Sprague-Dawley strain fed 
a single meal of 20 mg 7,12 DMBA in oil emulsion will 
develop mammary adenocarcinoma" (51). 
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Specific receptors for estrogen, progesterone, and 
prolactin have been demonstrated in DMBA induced tumors 
(38, 52). Receptor of DMBA induced tumors behaves like 
that of human mammary tumors with regard to range of 
concentrations, affinity (Kd), and molecular species by 
gradient centrifugation (21). It has been reported that 
among tumors induced by DMBA in rats of the Sprague-Dawley 
strain, 85-90% are estrogen receptor positive and 85% are 
progesterone receptor positive (53) 60% of DMBA tumors 
are prolactin dependent (54). 
DMBA induced carcinoma of the rat shares a number of 
characteristics with human breast cancer, as well as some 
differences. The common characteristics in biological 
behavior and response of cytostatic and endocrine therapy 
make chemically induced rat mammary carcinoma a suitable 
model for human breast cancer (55). In this investiga-
tion, cytoplasmic and nuclear binding sites for estrogen 
and progesterone in DMBA induced mammary carcinomas were 
analyzed by titration assay. Results were compared 
between two groups of tumors categorized by response to 
oophorectomy. In one group, termed hormone dependent, 
tumors regressed completely following oophorectomy. In 
the second group, termed hormone independent, tumors 
continued to grow. It is the purpose of this study to 
21 
examine the differences in steroid binding parameters 
between these two biologically defined tumor populations: 
MATERIALS AND METHODS 
Animal Treatment 
Immature female rats of the Sprague-Dawley strain 
were obtained from Harlan Industries, Indianapolis, Ind., 
housed in temperature- and light-controlled quarters, and 
supplied with water and Purina Laboratory Chow (Ralston 
Purina Co., St. Louis, Mo.) ad libitum. 
At age 50 ± 1 days, under light ether anesthesia, 
animals were administered a single feeding of 20 milli-
grams of 7,12 dimethylbenz(a) anthracene (DMBA), in 2 
milliliters of oil emulsion, by intra-gastric 
instillation. 
Beginning at one month after DMBA treatment, animals 
were palpated once a week for the appearance of mammary 
tumors. When the average diameter of a palpable tumor 
exceeded 2 cm., the animal was anesthetized with 
pentabarbital (the Butler Co., Columbus, 0.) at a dose 
of 3 - 4 mg per 100 g body weight intraperitoneally, and 
subjected to bilateral oophorectomy. At the time of 
surgery, tumors were measured with calipers and mapped. 
Approximately 1/2 of the tumor was removed for receptor 
analysis, leaving 1/2 part in the host for observation 
of .its growth pattern. 
Tumor biopsies were dissected free of connective 
22 
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tissue and debris, frozen on dry ice/acetone and stored 
at -20° C. 
Hormone Dependence 
If following oophorectomy, a tumor regressed 
completely it was termed hormone-dependent, and if it 
continued to grow it was termed hormone-independent, the 
period of observation being one month. For the hormone 
dependent group, biopsy material obtained at oophorectomy 
was utilized for receptor analysis. For the hormone 
independent group, animals bearing tumors which continued 
to grow following oophorectomy were stunned and decapi-
tated and tumor tissue was removed and processed as 
described for tissues obtained at oophorectomy. 
Reagents 
For binding experiments [2,3,4,5,16,17-
3
HJ estradiol 
- 17 beta (151 ci/mmol), [17 oc methyl - 3111 R5020 (17,21 
dimethyl-19-nor-4,9-pregnadiene-3,10-dione; 85 ci/mmol), 
and radioinert R5020 were obtained from New England 
Nuclear Corp. Unlabeled diethylstibestrol (DES), Tris 
preset crystals (pH 7. O at 27° Cl, a.nd n,n-dimethyl 
formamide were purchased from Sigma Chemical Co. 
ScintiVerse E was purchased from Fischer Scientific, and 
Analytical grade hydroxylapatite (DNA grade BioGel HTP) 
was purchased from BioRad. 
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Determination of Cytosol and Nuclear Binding Sites 
Binding site determinations employed and modifica-
tions of the hydroxylapatite methods of Chamness et al 
and Pavlik and Coulson (41, 57). All procedures were 
carried out on ice or refrigerated at O - 4° C, unless 
otherwise specified. 
Frozen tissue was weighed, minced on a cold glass 
plate and homogenized in buffer containing 10 rnM Tris 
0 
(pH 7.56 at O) and 7 1/2 percent n,n dimethylformamide 
(v/v). Homogenizations were carried out in a seven 
milliliter TenBroeck pyrex glass-glass tissue grinder 
at a ratio of approximately 100 mg tissue per ml buffer. 
The homogenate was centrifuged 10 minutes at 800 x g. 
The supernatant was further centrifuged for 50 minutes 
at 45,000 x g to yield the high speed supernatant 
(cytosol). The first pellet was resuspended in homo-
genization buffer and washed twice by centrifugation for 
10 minutes at 800 x g discarding the supernatants, then 
resuspended for one hour in homogenization buffer con-
taining 0.4 M potassium chloride for extraction of 
nuclear receptors. The pellet suspension was then 
centrifuged for 10 minutes at 3000 x g .and the super-
natant (nuclear extract) was assayed for nuclear 
receptors. 
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Five hundred microliter aliquots of cytosol or 
nuclear extract were incubated with four final concen-
trations of either [ 3H] estradiol - 17 Beta (.15, .5, 
3 3.0, 10.0 nM) or [ HJ R5020 (.5, 3.0, 15.0, 45 nM) in 
homogenization buffer. Reactions were performed in 
parallel with a 200 - fold excess of radioinert com-
petitor for determination of non-specific binding. DES 
was used in estrogen receptor assays and unlabeled 
R5020 was used in progesterone receptor assays. 
Incubations were for 16-18 hours at O - 4° C. The 
synthetic progestin R5020 is especially useful in 
receptor studies because it does not bi"nd to cortico-
steroid binding globulin (CBG) (11). Similarly, an 
important advantage of DES (a non-steroidal estrogen) is 
its low affinity for sex steroid binding globulin (SSBG) 
( 4 9) • 
Hydroxylapatite (HAP) 
At the end of incubation duplicate 200 microliter 
aliquots from each incubation tube were added to tubes 
containing one milliliter of 10% hydroxylapatite slurry 
(prepared by suspending 10 grams of DNA grade BioGel HTP 
in 100 ml of homogenization buffer). Adsorption to HAP 
was carried out for 45 minutes, ~ith occasional vortex 
mixing to maintain suspension. The HAP was then pelleted 
by centrifugation for 2 minutes at 800 x g. The pellet 
was washed three times with 2 ml homogenization buffer 
by centrifugation for 2 minutes at 800 x g, discarding 
the supernatants. 
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liound radioactive steroid was removed from HTP by 
extraction into 1.5 ml lOOi ethanol (30 minutes, room 
temperature), and then counted in 5 ml of scintillation 
fluid (ScintiVerse E, Fischer Scientific). All counts 
W<>re made in Packard TriCarb Model 300 Liquid 
Scintillation Spectrometer at Maxey Flats Low-Level 
Nuclear Waste Disposal Site. 
For the calculation of binding capacity (B ) and max 
affinity (dissociation constant, Kd), daia were plotted 
according to the method of Scatchard (46) and subjected 
to least squares regression analysis. Table 3 and 
Figure 2 depict representative titration data and 
Scatchard analysis. Total bound steroid (BT) is the 
amount of radioactive steroid bound in the absence of 
competitor. Non-specifically bound steroid (BNS) 
represents the amount of tritiated steroid bound in the 
presence of a 200-fold excess of radioinert competitor. 
Total radioactive steroid (Tl was estimated by direct 
sampling of incubates prior to the addition of the 
hydroxylapatite slurry. The quantities of BT, BNS' and 
T were determined by scintillation counting while 
specifically bound steroid (BS) was estimated by 
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subtracting BNS from BT, and total free steroid (F) was 
estimated by subtracting BT from T. Specifically bound 
steroid (BS), as the x-variable, was plotted against the 
bound to free ratio (Bs/F) as they-variable (Figure 2). 
A line was fitted to the data points by least squares 
regression analysis and B and Kd were estimated as max 
the x-intercept and - 1/slope, respectively. Bmax and 
Kd were calculated in terms of count rates (disintegra-
tions per minute, dpm) and then converted to molar 
concentrations. Estimated binding sites (the molar 
equivalent of B ) were standardized by protein concen-
max 
tration, as determined by the method of Lowry et al ( 56), 
with bovine serum albumin (1 mg/ml) as standard. The 
data were expressed as femptomoles of bound steroid per 
milligram of protein (fmol/mg) for estimated binding 
sites and moles per liter (Ml for Kd. 
Table 3. Representative Titration Data (Cytosolic 
3
H Estradiol Binding, 
Tumor Number 5) In Disintegrations Per Minute (dpm). 
BT= total bound, BNS = non-specifically bound, Bs = specifically 
bound (BT - BNS = Bs), T = total radioactive steroid added, and 
F = total free steroid (T - BT= F). 
BT BNS B T F B /F 
3H Estradiol Concentration 
s s 
66,139 54,691 11,448 656,300 590,161 .019 10.0 nM 
30,535 19,115 11,420 189,811 159,276 .072 3.0 nM 
11,529 3,819 7,710 45,500 33,971 .227 . 5 nM 







4 8 12 16 
BS (dpm x 10-3) 
Fig1Jre 2. Representative Scatchard Plot (cytosolic 
estrogen binding, tumor number 5). Bs 
(specifically bound} is plotted against 
Bs/F (bound to free ratio). A line was 
fitted by least squares regression. Gmp -
disintegrations per minute. 
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RESULTS AND DISCUSSION 
Estrogen and progesterone binding sites in tumor 
cytosol and nuclear extract were analyzed by multiple 
point titration assay for a total of eight tumors. 
Estimates of binding site concentration and dissocation 
constant (Kd) are summarized in Table 4. 
Analysis of estro~en receptors (ER) shows that 88% 
of tumors are positive for cytosol binding sites, 63% 
are positive for nuclear binding sites, and 50% are 
positive for both. Analysis of progesterone receptors 
(PR) shows that 50% are positive for cytosol binding 
sites and 50% are oositive for nuclear binding sites, 
while only one tumor is positive for both (tumor number 
3) • 
Estimates of dissociation constants of dissociation 
constants of 3H estradiol = 17 beta or 3H R5020 from 
their receptors indicate high affinity binding sites. 
Tumors from both groups (hormone-dependent and hormone-
independent) contained estrogen-receptor complexes with 
Kd values of CJ'\ l0-
9M, and R5020-receptor complexes with 
Kd values of Cll 10-sM. No significant differences were 
observed in the affinities of either of these binding 
sites between groups (Table 5), indicating that dif-
ferences in biological response were not correlated with 
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Table 4. Binding Data. Estimates Of Binding Site Concentrations (Expressed As 
Femptomoles Per Milligram Of Protein) and Kd (in parentheses). 
Tumor 
Number 
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Table 5. Average Dissociation Constant (Kd) Expressed 







3H estradiol - 17~ 
-9 .59 X 10 M 
1. 29 X 10- 9 M 
.88 X 10- 9 M 
3H R5020 
-8 2.0 X 10 M 
1.0 X 10- 8 M 
1.6 X 10- 8 M 
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alterations in the association action between the steroid 
and its receptor. 
Tables 6, 7, and 8 correlate all distributions of 
receptor occurring in the data set with response to 
oophorectomy. For groups containing more than one tumor, 
receptor status correlates most closely with regression 
when estrogen receptor is present in both the cytosol and 
nuclear extract or when both estrogen and progesterone 
receptor are present in the cytosol (75% and 67% regressed, 
respectively; A, tables 6 and 8). The one tumor con -
taining cytosolic and nuclear binding sites for both 
estrogen and progesterone (B, table 8) was hormone 
deoendent, in vivo. Likewise, the absence of either .. ---
cytosolic or nuclear estrogen receptor is associated with 
diminished regression rate in response to oophorectomy 
(0 and 33%; Band C, table 6). While considered by 
itself, the presence or absence of progesterone receptor 
is not distinguished by response to oophorectomy, the 
presence of cytosol progesterone receptor when estrogen 
receptor is also positive correlates with increased 
numbers of regressions. 
It should be noted that one tumor positive for both 
cytosolic and nuclear estrogen receptor, (D, table 6) 
and one tumor with cytosol positive for both estrogen and 
progesterone receptor, (C, table 8) was hormone 
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Table 6. Estrogen Receptor (ER) Distribution and 
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(PR) Distribution and 
Response to Oophorectomy. 
Number of Number of 
Receptor Status Total Number Regressed Growing 
Cytosol Nuclear of Tumors Tumors Tumors 
PR+ 4 2 (50%) 2 
PR- 4 2 ( 50%) 2 
PR+ 4 2 ( 50 % ) 2 
PR- 4 2 ( 5 0%) 2 
PR+ PR+ 1 1 (100%) 0 
PR+ PR- 3 1 (33,%) 2 
PR- PR+ 3 1 (33%) 2 
PR- PR+ 1 (A) 1 (100%) 0 
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Table 8. Distribution and Response To Oophorectomy. 
Estrogen and Progesterone Receptor. 
Receptor Status Number of Number of Total Number Regressed Growing 
Cytosol Nuclear of Tumors Tumors Tumors 
ER+PR+ 3 (A) 2 (67%) (C)l 
ER+PR- 4 2 ( 50%) 2 
ER-PR+ 1 0 1 
ER+PR+ 1 1 (100%) 0 
ER+PR- 4 2 ( 5 0 % ) 2 
ER-PR+ 3 1 ( 3 3%) 2 
ER+PR+ ER+PR+ 1 (B)l (100%) 0 
ER+PR+ ER+PR+ 2 1 (50%) 1 
ER+PR- ER+PR- 1 1 (100%) 0 
ER+PR- ER-PR+ 3 (D)l (33%) 2 
ER-PR+ ER+PR- 1 0 1 
,, 
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independent in vivo. Also, one tumor which was negative 
for progesterone receptors, both cytosolic and nuclear, 
(A, table 7) and one tumor which was negative for nuclear 
estrogen receptor and cytosolic progesterone receptor, 
(D, table 8) were hormone-dependent in vivo. It has been 
shown that prolactin can stimulate estrogen receptor ,in 
mammary tumors (58) and it is unknown whether progestin 
receptors are dependent on estrogen action directly or 
estrogen induced prolactin secretion (59). The presence 
of prolactin binding in the absence of estrogen binding 
can be associated with autonomous growth (22). Prolactin 
dependence may explain the presence of ER and PR in these 
"hormone-independent" tumors, and conversely, sensitivity 
to alterations in prolactin concentration may be responsi-
ble for regression of the two tumors with minimal estro-
gen and progesterone receptor populations. The same 
model of prolactin dependence can account for the regres-
sion of tumors which are steroid receptor negative and 
the continued growth of steroid receptor positive tumors 
following oophorectomy. 
Mean receptor concentration was higher for both 
hormones in both locations, cytosol and nuclear extract, 
in the hormone dependent group (Table 9). Differences 
between groups did not attain statistical significance. 
Inspection of the binding data indicates that mean binding 
Table 9. Average Receptor Concentration Expressed As Femptomoles Per Milligram 









23.6 + 28.6 
12.2 + 9.0 
+ 17.9 20.6 
+ 24.7 32.5 
8.1 + 14.7 
16.4 + 24.9 
3H 
cytosol 
267.0 + 403.7 
56.8 + 71.0 
161.9 + 290.9 
R5020 
nuclear 
139.1 + 223.7 
36.2 + 43.2 
87.7 + 158.9 
w ...., 
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site concentrations in the hormone dependent group are 
shifted upward by the pr•,•sence in each hormone receptor 
location of one tumor with a binding capacity several 
fold larger than the rest, (A,B,C,D; Table 4). The 
observation that very high binding capacity in each case 
is associated with hormone independence is particularly 
interesting in light of the suggestion by several 
investigators that hormone dependency among breast 
tumors may represent a continuous function of receptor 
concentration (29). 
SUMMARY 
Normal breast tissue contains specific binding sites 
for each of the hormones known to influence its growth or 
development. With malignant transformation, cells may 
retain all or only part of the normal population of 
receptor sites. If a cell retains receptors, it remains 
at least potentially capable of being regulated by the 
hormonal environment. If receptor sites are lost, the 
cell may escape from endocrine control (22). 
The results of this investigation suggest a corre-
lation between increasing estrogen and progesterone 
receptor populations in the qualitative sense and 
increasing numbers of regressions in response to 
oophorectomy, and perhaps a quantitative relationship 
between steroid receptor concentration and hormone-
dependence in vivo. The relationship between inter-
mediate receptor populations and intermediate binding 
capacities is unreliable however, and suggests the need 
for evaluation of binding parameters for other hormones 
influencing breast growth and function, particularly 
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